Design Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -151 | 14,741 | -14,589 | |
EBITDA | -22,026 | -17,479 | -15,841 | -16,842 |
EBIT | -22,177 | -17,636 | -15,997 | -16,997 |
Net Income | -20,165 | -17,636 | -15,997 | -16,997 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -15,545 | -16,431 | -12,000 | -11,162 |
Cash | 12,907 | 12,770 | 16,856 | 15,088 |
Basic Shares | 62,505 | 61,434 | 57,330 | 56,950 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -622 | -596 | -537 | -466 |
EBITDA | -69,170 | -48,992 | -66,325 | -67,187 |
EBIT | -69,792 | -49,588 | -66,862 | -67,593 |
Net Income | -69,792 | -49,588 | -66,862 | -58,617 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -272,069 | |||
Free Cash Flow | -54,551 | -43,445 | -58,816 | -52,235 |
Cash | 16,856 | 22,563 | 21,200 | 26,500 |
Basic Shares | 57,330 | 56,587 | 55,984 | 55,707 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.32 |
2026-03-31 | -$0.29 |
2025-12-31 | -$0.27 |
2025-09-30 | -$0.30 |